lxh254
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 18, 2016 (NCT02607813)
Timeline
Indications
Mechanism of action
- BRAF/CRAFINHIBITOR
BRAF/CRAF inhibitor
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
Selective for b-RAF/c-RAF vs. a-RAF.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1- Mol. weight
- 502.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4583691 ↗
Also known as
- lxh254
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06346067 | Phase 3 | Apr 29, 2024 | Erasca, Inc. |
| NCT05907304 | Phase 1 | Aug 17, 2023 | Erasca, Inc. |
| NCT04417621 | Phase 2 | Jul 13, 2020 | Novartis |
| NCT04294160 | Phase 1 | May 26, 2020 | Novartis |
| NCT03333343 | Phase 1 | Jan 29, 2018 | Novartis |
| NCT02974725 | Phase 1 | Feb 24, 2017 | Novartis |
| NCT02607813 | Phase 1 | Jan 18, 2016 | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 2 | 2016 |
| Erasca, Inc. | For profit | 2 | 2 | 2 | 2023 |
2 organizations
Page 1 / 1